PPD/Takeda submit Japanese NDA for alogliptin
The USA's PPD says marketing partner Japan's Takeda has submitted a New Drug Application to the Ministry of Health Labor and Welfare for alogliptin, a highly- selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Under the terms of the firms' agreement, the submission will trigger a $3.0-million milestone payment to PPD. The drug was accepted for filing by the US Food and Drug Administration earlier this year (Marketletter March 10). Takeda bought the rights to the agent from PPD for an upfront fee of $15.0 million in 2005.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze